Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Tegoprazan in H. pylori Positive and Negative Volunteers
NCT03009760Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jan 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (4 arms), sponsored by HK inno.N Corporation. Primary endpoint: Peak Plasma Concentration up to 12 hours. Started Jan 2015; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03009760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009760.